跳至主要内容
临床试验/NCT03354065
NCT03354065已完成不适用

Inmediate Feeding Tolerance in Patients With Mild and Acute Biliary Pancreatitis vs Early Feeding

Hospital Central "Dr. Ignacio Morones Prieto"0 个研究点目标入组 59 人开始时间: 2017年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
59
主要终点
Pancreatitis reactivation after oral Feeding

研究概览

简要总结

Objective: Determine tolerance of immediate oral intake (8 hours posterior to the beginning of treatment) against traditional management (early feeding at 48hr) in patients with mild acute pancreatitis of biliary origin.

Double blind, randomized clinical trial

详细描述

The investigators included patients 15 - 85 years old, any sex. Diagnosis of mild acute pancreatitis according to the Ranson, APACHE II and BISAP.

Signed infromed consent to participate in the study. All participants had a hepatic and biliary ultrasound to determine the biliary etiology.

The investigators excluded patients with pancreatitis of nonbiliary etiology, pregnant, severe pancreatitis, cholangitis or choledocholithiasis demonstrated during the hospital stay or with other comorbidities.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

blinding of the evaluator to the study group blinding of patient to study hypothesis

入排标准

年龄范围
15 Years 至 85 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 15 years.
  • Patients with a diagnosis of mild acute pancreatitis biliary.
  • Patients who agree to enter the protocol.

排除标准

  • Patients managed at another institution.
  • Patients with a diagnosis of pancreatitis of non-biliary etiology.
  • Patients with heart disease or lung disease.
  • Patients with organic failure.
  • Patients with pregnancy.
  • Patients with cholangitis.

结局指标

主要结局

Pancreatitis reactivation after oral Feeding

时间窗: Measures at 48hours after the begining of the oral intake

Resurgence of characteristically epigastric tansfictive pain, irradiated to the left, upper quadrant region after beginning the oral intake, systemic inflammatory response syndrome ( C reactive protein) or Significant leucocyte elevation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Esmer

head of the surgery service of Central Hospital, SLP, Mex

Hospital Central "Dr. Ignacio Morones Prieto"

相似试验